NIH grants were cut 66%. 383 clinical trials halted. 74,000 patients lost access to experimental treatments. Cancer researchers, Alzheimer's teams, and rare disease specialists lost funding mid-study. The patients enrolled in those trials had no other options.
Restore NIH funding to at least FY 2024 levels. Reverse the grant cuts that halted active clinical trials. Patients waiting for treatments that were working should not lose access because of a budget decision.